---
title: "Shukra Pharmaceuticals Ltd (524632) — Share Price, Financials & Analysis"
symbol: "524632"
company: "Shukra Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/524632"
isin: "INE551C01044"
nse_symbol: "SHUKRAPHAR"
bse_code: "524632"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 2390.62
generated_at: "2026-09-13T19:16:44.995Z"
---

# Shukra Pharmaceuticals Ltd (524632)

Canonical page: https://tapetide.com/stocks/524632

## Company

- **NSE Symbol:** SHUKRAPHAR
- **BSE Code:** 524632
- **ISIN:** INE551C01044
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2026-08-14
- **CEO:** Mr. Dakshesh Rameshchandra Shah
- **Employees:** 115
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** shukrapharmaceuticals.com

## About

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]

## Latest Price

- **Price:** ₹53.94
- **Change:** -0.03 (-0.06%)
- **Open:** ₹54.05
- **Day High:** ₹55.6
- **Day Low:** ₹53.75
- **Previous Close:** ₹53.97
- **Volume:** 1577298
- **As Of:** 2026-09-11T09:59:53+00:00

## Key Fundamentals

Observed at 2026-09-11T04:47:53.089259Z.

- **Market Cap:** ₹2390.62 Cr
- **Classification:** Microcap
- **P/E (reported):** 70
- **P/E (TTM):** 66.59
- **EPS (TTM):** ₹0.81
- **Book Value:** ₹2.27
- **Price to Book:** 23.72
- **Dividend Yield:** 0.02%
- **ROE:** 15.24%
- **ROCE:** 20.05%
- **Debt to Equity:** 0.06
- **Revenue (yearly):** ₹56.71 Cr
- **Net Income:** ₹19.83 Cr
- **EBITDA:** ₹28.73 Cr
- **52-Week High:** ₹58.2
- **52-Week Low:** ₹40.06
- **RSI (14):** 83.67

## Tapetide Score

- **Score:** 49 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 43.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 89.26 | 9% |
| growth | 98.9 | 9% |
| momentum | 68.69 | 12% |
| ownership | 54.32 | 24% |
| quality | 59.32 | 22% |
| valuation | 19 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 175% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%

### Weaknesses

- Stock is trading at 26.3 times its book value
- Debtor days have increased from 122 to 148 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 252.31% | 149.84% | — |
| ebitda margin growth | — | 1.85% | 63.29% | 225.1% |
| net income growth | 864.71% | 106.56% | 71% | 175% |
| revenue growth | 230.14% | 54.1% | -1% | 38% |
| roce | — | -36.69% | 37.8% | 14.49% |
| roe | — | -52.61% | 21.61% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 2 |
| Operating Profit | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | 0 | 27 | 1 | 21 |
| OPM % | 21 | 51 | 41 | 25 | 12 | 37 | 55 | 24 | -7 | 69 | 11 | 90 |
| Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 20 |
| Tax % | 0 | 1 | 24 | 41 | 39 | 23 | 29 | 26 | -1090 | 24 | 568 | 26 |
| Net Profit | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 15 |
| EPS in Rs | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.34 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 75 |
| Expenses | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 26 |
| Operating Profit | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 49 |
| OPM % | 30 | 29 | 13 | 13 | 14 | 9 | 26 | 39 | 51 | 65 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 48 |
| Tax % | 45 | 37 | 82 | -90 | 26 | 1 | 7 | 28 | 23 | — |
| Net Profit | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 36 |
| EPS in Rs | 0.01 | 0.01 | 0 | 0 | 0.02 | 0.1 | 0.42 | 0.22 | 0.5 | 0.81 |
| Dividend Payout % | 15 | 17 | 0 | 0 | 10 | 4 | 6 | 5 | 2 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 |
| Reserves | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 46 |
| Borrowings | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 5 |
| Other Liabilities | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 23 |
| Total Liabilities | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
| Fixed Assets | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 22 |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 84 |
| Total Assets | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 |
| Cash from Investing Activity | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 |
| Cash from Financing Activity | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 |
| Net Cash Flow | -1 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -1 | -4 | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/OP | 7 | 63 | 25 | 81 | 38 | 292 | 64 | -24 | 92 | 17 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 | 148 |
| Inventory Days | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 | 320 |
| Days Payable | 400 | 734 | 1161 | 786 | 702 | 303 | 271 | 59 | 414 | 232 |
| Cash Conversion Cycle | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 | 236 |
| Working Capital Days | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 404 | 352 |
| ROCE % | 7 | 6 | 4 | 0 | 1 | 6 | 19 | 44 | 22 | 37 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 50.9% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 29.14% | 28.94% | 9.79% | 9.19% | 9.25% | 9.41% | 9.29% | 28.69% | 9.2% | 9.43% | 9.37% | 9.38% |
| Others | 19.85% | 19.99% | 39.14% | 39.73% | 39.68% | 39.51% | 39.64% | 20.24% | 39.72% | 39.5% | 39.56% | 39.55% |
| No. of Shareholders | 9747 | 10963 | 12974 | 14989 | 16321 | 17844 | 18231 | 20337 | 21441 | 25649 | 27173 | 28384 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 5 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 51.07 | Buy |
| EMA (10) | 51.48 | Buy |
| SMA (20) | 47.23 | Buy |
| EMA (20) | 47.78 | Buy |
| SMA (50) | 39.19 | Buy |
| EMA (50) | 41.57 | Buy |
| SMA (100) | 34.8 | Buy |
| EMA (100) | 38.36 | Buy |
| SMA (200) | 39 | Buy |
| EMA (200) | 35.94 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 78.76 | Sell |
| MACD (12,26,9) | 4.62 | Buy |
| Stochastic (14,3,3) | 76.98 | Neutral |
| ADX (14) | 51.58 | Buy |
| Williams %R (14) | -30.15 | Neutral |
| ATR (14) | 2.84 | High Volatility |
| ROC (12) | 22.09 | Buy |
| Stoch RSI (14) | 22.45 | Neutral |
| UO (7,14,28) | 38.57 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-05 | [AGM NOTICE](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07641637-bb85-4609-93e2-5f876ca2b26f.pdf) |
| 2026-09-05 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65eccf64-a818-4453-b3b9-b7db41e70fe1.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Dividend Updates](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2adb6669-72e3-4df3-ae39-0b83e60fa629.pdf) |
| 2026-09-03 | [Update On Date Of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e389e5b-8b95-4c9f-a61b-cf7109c16455.pdf) |
| 2026-09-02 | [Board Meeting Outcome for Allottment Of Preference Shares](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff39583d-966e-4468-90d9-76fb41db0935.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f1701ad-30cc-4d99-a282-40edd491f73b.pdf) |
| 2026-08-27 | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc72bf92-fe53-4857-ab1d-4551b8fb6157.pdf) |
| 2026-08-22 | [Board Meeting Outcome for AGM And Change Of Name](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3aeffa39-4654-4752-a075-eb6a8a87dd08.pdf) |
| 2026-08-17 | [Board Meeting Intimation for AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0977be9b-b9fd-4d4e-8f77-940c95dcd3ab.pdf) |
| 2026-08-17 | [Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cdc75b93-6f07-4a8f-9898-0a2a096f3d44.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Quarterly Results June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79dc8d54-c74e-48b5-9bf7-182fb759edd4.pdf) |
| 2026-05-07 | [Results For The Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d329ef27-4161-468e-b500-a5fcee0de3ee.pdf) |
| 2026-02-04 | [Unaudited Financial Results For The Quarter Ended December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1030191f-8f92-4838-9bcf-e8696d848866.pdf) |
| 2025-11-13 | [Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30 2025 Along With The Auditors Limited Review Reports In Accordance With The Provisions Of Regulation 33 Of The SEBI Listing Regulations.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7d36c61-1117-48a6-bb19-2de49459bb93.pdf) |
| 2025-08-13 | [Un-Audited Financial Results Of The Company For The First Quarter Ended June 30 2025 Along With The Auditors Limited Review Reports In Accordance With The Provisions Of Regulation 33 Of The SEBI Listing Regulations.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dd1a4f4-8a3b-494d-9305-e67f825c22a6.pdf) |
| 2025-05-29 | [Audited Financial Statement For The Quarter And Year Ended On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d2396d5-4aec-4d93-bc94-f1f2d535f26d.pdf) |
| 2025-02-14 | [Submission Of Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended On 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd540197-5ca9-4c58-8e8c-67b3620d3773.pdf) |
| 2024-11-14 | [Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended On 30Th September, 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eef0e6af-f378-4e51-933f-fce31b0e48cd.pdf) |
| 2024-08-12 | [Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a82282f2-6392-4b63-b0ed-580ca035e01f.pdf) |
| 2024-05-29 | [Standalone Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c48c327-a891-4add-be42-6b007a122ec4.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 May - FY26 audited results announced; board recommended 0.01 dividend and allotted 17.35 lakh promoter shares on May 7. | [Announcement under Regulation 30 (LODR)-Allotment 7 May - FY26 audited results announced; board recommended 0.01 dividend and allotted 17.35 lakh promoter shares on May 7.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4505779d-ba01-41b5-997c-12ebfc819a1b.pdf) |
| 7 May - Board approved FY26 audited results, Rs.0.01 dividend, and allotted 17.35 lakh shares on warrant conversion. | [Corporate Action-Board approves Dividend 7 May - Board approved FY26 audited results, Rs.0.01 dividend, and allotted 17.35 lakh shares on warrant conversion.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7a2b61ba-7d3e-41f1-aa72-82cb2d4a5bc9.pdf) |
| 7 May - Board approved FY26 audited results, 0.01 dividend, and allotment of 17.35 lakh warrant-conversion shares. | [Board Meeting Outcome for Outcome For The Board Meeting Dated 07.05.2026 For The Audited Financial Results For The Quarter And Year Ended March, 2026 7 May - Board approved FY26 audited results, 0.01 dividend, and allotment of 17.35 lakh warrant-conversion shares.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/dcae535a-83fb-4a6a-942d-49751dadc2d8.pdf) |
| 7 May - Annual secretarial compliance report for FY2026 notes compliance, minor past fines, preferential warrant issue and director changes. | [Compliances-Reg.24(A)-Annual Secretarial Compliance 7 May - Annual secretarial compliance report for FY2026 notes compliance, minor past fines, preferential warrant issue and director changes.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/49568d11-0dcd-40c9-8b3e-a2ce925cba94.pdf) |
| 6 Mar - Shukra Pharmaceuticals: Independent Directors meeting on 16 March 2026 to review board and chairman performance. | [Board Meeting Intimation for Independent Directors Meeting 6 Mar - Shukra Pharmaceuticals: Independent Directors meeting on 16 March 2026 to review board and chairman performance.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ceaa9e51-34f7-49dd-867f-30e62ef10312.pdf) |
| 4 Feb - Q3 & nine-month unaudited: Total income ₹3,995.01L; Net profit ₹2,036.46L; MD re-appointed 30/12/2025–30/12/2030. | [Board Meeting Outcome for Outcome Of The Meeting Of Board Held On Wednesday, February 04, 2026 4 Feb - Q3 & nine-month unaudited: Total income ₹3,995.01L; Net profit ₹2,036.46L; MD re-appointed 30/12/2025–30/12/2030.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/155dc7e3-6cbd-4294-99a3-aeaa3bc6d4e0.pdf) |
| 30 Jan - Board meeting on 7 Feb 2026 to approve Q3 unaudited results (31 Dec 2025) and limited review report. | [Board Meeting Intimation for Unaudited Financial Result For The Third Quarter Ended On 31 December, 2025 Along With The Auditor''s Limited Review Report. 30 Jan - Board meeting on 7 Feb 2026 to approve Q3 unaudited results (31 Dec 2025) and limited review report.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b543962f-e7e3-41ef-9699-c72a5cfc4cd7.pdf) |
| 30 Jan - Board meeting 4 Feb 2026 to approve unaudited Q3 results for quarter ended 31 Dec 2025. | [Update on board meeting 30 Jan - Board meeting 4 Feb 2026 to approve unaudited Q3 results for quarter ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fa36df5b-4df5-40a7-ad6f-bac566430ecd.pdf) |
| 3 Feb - Earnings call scheduled Feb 11, 2026 at 15:00 IST for Q3FY26 results release. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Feb - Earnings call scheduled Feb 11, 2026 at 15:00 IST for Q3FY26 results release.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b09163c0-80f7-4123-9606-1ac29ea81ffb.pdf) |
| 2d - Newspaper publication of Standalone Audit Financial Results for Fourth Quarter and Financial Year ended on 31st March 2026 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 2d - Newspaper publication of Standalone Audit Financial Results for Fourth Quarter and Financial Year ended on 31st March 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c90acecb-a218-4677-8beb-8464c669e795.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bd0db744-7bda-4476-8aa2-a966a585f084.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5acf8bf7-f982-4505-989d-179d13318b84.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/993e7524-b3b5-4889-83a9-97caea251c8f.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8114e526-7445-4a31-93b7-8a5e01acdc0c.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f29b390-ce26-4f7d-b67e-740177e082de.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/35db8a1c-4697-473d-b6a4-8670ba6b5e43.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/49127dac-7949-4649-ace1-b62bfc5dd2ac.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6b8880f6-0a64-459c-882e-758981cd0182.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c61f7528-0d84-4cf8-83c4-205fc430e94d.pdf) |
| Feb 2024 | [Concall - Feb 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b994e9b-5004-4081-b47e-8455d8940e2c.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_412_DIVISLAB_2012_2013_11072013110311.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/689429a5-a286-4554-806e-b366d72d68f0.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/06c1ebd6-96d9-4618-93c4-a5dfa4e9fe72.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c99c2f71-c746-4a3b-9315-e12353fa03f5.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0697acda-e231-41d2-a627-1968b0b5ef9e.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/53e51bb0-ffb0-4e50-81da-d876f1a00fe8.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/302e7894-3b41-4867-abb8-14268f914a40.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532488/73877532488.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524632/76257524632.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532488/69212532488.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:16:44.995Z.